Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adherex Technologies has completed patient enrollment in the Phase I portion of the clinical trial of systemic ADH-1, in combination with isolated limb infusion melphalan and is proceeding with a multi-institutional Phase IIb expansion of the melanoma study.
Subscribe to our email newsletter
The company plans to expand the clinical trial of systemic ADH-1 in combination with isolated limb infusion melphalan for the treatment of melanoma by up to 25 additional patients. Further, the M D Anderson Cancer Center in Houston, Texas has been added as an additional clinical trial site to gain multi-institutional experience. This Phase IIb expansion of the trial is anticipated to complete patient accrual by approximately mid-2008 and data will be released at an appropriate scientific venue.
William Peters, chairman and CEO of Adherex, said: “We have completed the Phase I portion of this study at Duke with a satisfactory safety profile at all three ADH-1 doses tested and initial tumor response data that have exceeded our expectations based upon the center’s historical experience with mephalan alone.”